Plitidepsin
chemical compound
Plitidepsin, also known as dehydrodidemnin B and sold under the brand name Aplidin, is a chemical compound extracted from the ascidian Aplidium albicans.
Medical uses
In Australia, plitidepsin, in combination with dexamethasone, is indicated for the treatment of people with relapsed and refractory multiple myeloma.
Pharmacological activity
Plitidepsin exhibits antitumor, antiviral and immunosuppressive activities. It shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers.
Plitidepsin inhibits the human protein eEF1A which has potential interactions with multiple coronavirus proteins. Plitidepsin possesses antiviral activity against SARS-CoV-2 in vitro and in an in vivo mouse model.
Society and culture
Legal status
In July 2003, plitidepsin was granted orphan drug status by the European Medicines Agency (EMA) for treating acute lymphoblastic leukemia. In December 2017, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorization for the treatment of multiple myeloma. After a re-examination of the opinion, the refusal of the marketing authorization was confirmed in March 2018. The CHMP is of the opinion that the benefits of Aplidin do not outweigh its risks.
The public source identifies “Plitidepsin” as chemical compound. This brief keeps that definition visible, then builds a research path around Plitidepsin, chemical and compound.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Plitidepsin”, the useful work is to connect “chemical compound” to the records capable of establishing context and consequence.
The date and method of observation matter as much as the stated conclusion, especially where classification or consensus has changed. The source revision retrieved here is dated Feb 23, 2026. The linked authority identifier is Q4779975. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2003, 2017 and 2018.
Scientific names, classifications and consensus can change while older terminology persists in catalogues and historical literature. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Plitidepsin”, its source revision and the description used here.
- Expand the search: follow Plitidepsin primary sources, Plitidepsin archive and Plitidepsin research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Plitidepsin”?
- Has classification or technical consensus changed since the cited source?
- Which observation, specimen, dataset or publication supports the account?
Search terms from this dossier
This entry incorporates text from “Plitidepsin” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.